Key statistics
On Friday, AIM ImmunoTech Inc (AIM:ASQ) closed at 0.9076, 22.38% above the 52 week low of 0.7416 set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.95 |
|---|---|
| High | 0.98 |
| Low | 0.8728 |
| Bid | 0.884 |
| Offer | 0.93 |
| Previous close | 0.99 |
| Average volume | 619.66k |
|---|---|
| Shares outstanding | 3.98m |
| Free float | 3.87m |
| P/E (TTM) | -- |
| Market cap | 3.62m USD |
| EPS (TTM) | -19.82 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 20:56 GMT.
More ▼
- AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
- AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
- AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
- CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
- AIM ImmunoTech Announces Commencement of Rights Offering
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
- AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
- AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
- AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
More ▼
